e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Maintenance treatment with erlotinib after induction chemotherapy for advanced NSCLC
B. Coudert (Dijon, France)
Source:
Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer
Session:
Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer
Session type:
Hot topics
Number:
3389
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Coudert (Dijon, France). Maintenance treatment with erlotinib after induction chemotherapy for advanced NSCLC. Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009
Gemsitabine plus cisplatine therapy in local advanced NSCLC
Source: Eur Respir J 2007; 30: Suppl. 51, 434s
Year: 2007
Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015
Efficacy of induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): update of CT/RT 99/97
Source: Annual Congress 2004 - Management of lung cancer and innovative therapies
Year: 2004
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019
Year: 2020
Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Locally advanced inoperable non-small cell lung cancer (NSCLC) treated by weekly paclitaxel/carboplatin chemotherapy with concomitant radiotherapy
Source: Eur Respir J 2007; 30: Suppl. 51, 433s
Year: 2007
Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005
Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002
Second-line weekly docetaxel in advanced non-small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 377s
Year: 2001
Phase I trial of pemetrexed, carboplatin and sorafenib as first-line treatment in patients with metastatic NSCLC
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Treatment of advanced non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer
Source: Eur Respir J 2015; 46: 219-229
Year: 2015
Concurrent chemoradiotherapy with carboplatin and paclitaxel followed by consolidation chemotherapy with vinorelbine for locally advanced inoperable nonsmall-cell lung cancer: A multiinstitutional phase II study
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Weekly chemotherapy with cisplatin and paclitaxel in inoperable advanced non-small cell lung cancer: an extended phase II study
Source: Eur Respir J 2005; 26: Suppl. 49, 12s
Year: 2005
Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Role of adjuvant/neoadjuvant treatment in stage I NSCLC
Source: International Congress 2014 – Current therapeutic options in stage I non-small cell lung cancer (NSCLC)
Year: 2014
Indcution chemotherapy and radiotherapy
vs.
induction and simultaneous radiochemotherapy in inoperable stage III NSCLC. Update on BROCAT study CTRT 99/97
Source: Eur Respir J 2006; 28: Suppl. 50, 833s
Year: 2006
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
PRO: maintenance chemotherapy after induction chemotherapy for advanced nonsmall cell lung cancer
Source: Annual Congress 2011 - Pro/Con debate: Maintenance chemotherapy after induction chemotherapy for advanced nonsmall cell lung cancer
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept